AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05624294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS0159
Description: Tablets administered orally
Study NCT05624294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets administered orally
Study NCT04997733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT)
Description: The colonoscopy for FMT will be planned between 7 and 14 days after the last adalimumab or sub-cutaneous infliximab administration and 6 weeks +/- 7 days after the last intravenous infliximab administration 14 and 28 days following the last sub-cutaneous golimumab administration. After colon cleansing using polyethylene glycol, the patient will have a colonoscopy under general anesthesia. The patient will then receive either FMT (frozen preparation of 50g of stools in 300ml of saline (NaCl 0.9%), (FMT vehicle in the terminal ileum or the colon.~At W12 and W24 after first colonoscopy, the patient receives treatment by capsule (15 capsules contain 0.8g of stools by visit).
Study NCT04997733 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham-transplantation (placebo)
Description: The colonoscopy for sham-transplantation will be planned between 7 and 14 days after the last adalimumab or sub-cutaneous infliximab administration and 6 weeks +/- 7 days after the last intravenous infliximab administration, 14 and 28 days following the last sub-cutaneous golimumab administration. After colon cleansing using polyethylene glycol, the patient will have a colonoscopy under general anesthesia. The patient will then receive either sham transplantation (frozen preparation of NaCl 0.9% with 10% glycerol) in the terminal ileum or the colon.~At S12 and S24 after first colonoscopy, the patient receives treatment by capsule (15 capsules contain placebo).
Study NCT05172141 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI314(low dose)
Description: intravenously, once, on Day 1
Study NCT05172141 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI314(high dose)
Description: intravenously, once, on Day 1
Study NCT05172141 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI314(medium dose)
Description: intravenously, once, on Day 1
Study NCT05172141 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenously, once, on Day 1
Study NCT05573087 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aquatic Based Exercise
Description: 10 minutes of exercise with two 20 second sprints three days per week for 8 consecutive weeks
Study NCT05573087 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Land Based Exercise
Description: 10 minutes of exercise with two 20 second sprints three days per week for 8 consecutive weeks
Study NCT04186299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Each patient will receive a buccal infiltration of 1.7mL of 1:100,000 clonidine.
Study NCT04186299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Articaine Hydrochloride + Epinephrine
Description: Each patient will receive a buccal infiltration of 1.7mL of 4% articaine with 1:100,000 epinephrine.
Study NCT04186299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Articaine Hydrochloride + Epinephrine
Description: Each patient will receive a buccal infiltration of 1.7mL of 4% articaine with 1:100,000 epinephrine.
Study NCT04643860 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Differential Leucocyte Count (CLDC) device and algorithm
Description: Boold sample that detecting the early rise in leukocyte levels which has a characteristic set of ratios of leukocyte types, which identify the viral pathogen and distinguish it from a number of others. This test allows prediction of positives from full blood count results.
Study NCT04963439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: Macitentan dispersible tablets will be administered orally as per assigned treatment sequence.
Study NCT05692375 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Invitation to play the game Save the shame!
Description: The experimental group was asked to use the game. Two weeks were defined as the time to use the game. The use of the game can be seen by the coded digital record on its digital platform . The control group neither used nor had access to the game. Afterwards both groups performed the ALS knowledge assessment test. It is a test with 20 multiple choice questions each scored as right (0.5 points) or wrong (0 points).
Study NCT05410210 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care
Description: The clinical pharmacists will conduct medication reviews, patient education, and counseling. Moreover, the clinical pharmacists will identify drug-related problems (DRPs) and provide the information through written pharmacist notes to physicians at the clinic.
Study NCT06130488 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KMC
Description: KMC implementation as per protocol
Study NCT05114954 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioPulsesTM pulsed field ablation system
Description: Using pulsed field ablation (PFA) catheter, steerable sheath and pulsed field generator to treat atria fibrillation.
Study NCT05259189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBL-012 Injection
Description: a single subcutaneous injection
Study NCT05259189 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a single subcutaneous injection
Study NCT06371092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UltraEZ
Description: General examination with bite-wings. Dental prophylaxis (dental scaling and polishing with an abrasive paste). Alginate impressions of both arches. Creation of individualized bleaching trays and a position-finder tray of both arches. Application of the UltraEZ gel in the bleaching trays for 30 minutes. Application of the bleaching gel in the bleaching trays during 6-8 hours
Study NCT06371092 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: General examination with bite-wings. Dental prophylaxis (dental scaling and polishing with an abrasive paste). Alginate impressions of both arches. Creation of individualized bleaching trays and a position-finder tray of both arches. Application of the placebo gel in the bleaching trays for 30 minutes. Application of the bleaching gel in the bleaching trays during 6-8 hours
Study NCT04939714 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational Intervention
Description: The intervention is an online course providing education and training to caregivers over an 8 week period. The self-paced course provides information on caregiving for a PLWD during a pandemic, navigating the health care system for a PLWD, and managing daily life (including self-care).
Study NCT06209346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TeleRehab Group
Description: The duration of treatment for the Experimental Group will be 8 weeks and will consist of a total of 20 sessions, with between 2 and 3 sessions per week depending on the week they are in.~Weeks 2, 4, 6 and 8 will have 2 sessions per week and weeks 1, 3, 5 and 7 will have 3 sessions per week.~These sessions will consist of videos that will make up the educational material, videos that will guide the ET program and respiratory control practices.All the sessions mentioned above will be in online format, through the TRAK platform.
Study NCT06209346 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Advices Group
Description: They will receive informative material in weeks 1, 3, 5 and 7 about their pathology and with recommendations for them to achieve healthy lifestyle habits that do not further damage their disease. Participants in the Control Group will have the same follow-up evaluations as the Experimental Group and will receive informative material. They will not have access to the audiovisual material generated for the Experimental Group.
Study NCT05114577 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery Sleepers program.
Description: Attend two, 90-minute remote discussion groups (\~10 other participants and 2 study team members) via Zoom. During these groups, participants will receive educational materials about how to improve sleep. They will also discuss sleep and sleep-related behaviors, including how active substance use and recovery may have changed sleep, with a small group of other participants.
Study NCT05114577 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Email recommendations
Description: Receive recommendations (via email) to help improve sleep
Study NCT05588687 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Children will watch Ice Age in virtual reality during blood draw and the researcher will monitor their pain, anxiety and fear.
Study NCT05588687 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tablet
Description: Children will watch Ice Age with a tablet during blood draw and the researcher will monitor their pain, anxiety and fear.
Study NCT03211910 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SacralSaver
Description: Sacral Savers is a combination of a strong bubble wrap sheet with a fold at the head end and a nylon sham with a pocket into which the bubble wrap sheet is inserted. This combination is then placed under the fitted sheet on the patient's mid back and the pressure exerted by the lower back of the patient is markedly reduced or nearly eliminated (tested and proven using computer models), thereby preventing the onset of pressure ulcers in the sacro-coccygeal area.
Study NCT03211910 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Care of Treatment
Description: Standard Care of Treatment
Study NCT05555056 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MxN-9 HD-tES Stimulator (Soterix Inc.)
Description: Patients will be stimulated with high definition transcranial direct current stimulation (HD-tDCS) for 5 weeks (every weekdays; one session per day). In each session, a constant current at 2mA will be passed on the target brain areas for 20 minutes.
Study NCT05555056 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: The same stimulation protocol will be used as in Active stimulation except that a sham mode will be selected in the stimulator machine.
Study NCT05241457 — intervention group
Intervention type: DEVICE
Intervention: Ekso gait training
Description: Ekso sessions will be 60 minutes each. Patients will be measured to optimize Ekso fit during their initial training session. Ekso settings will be progressed as deemed appropriate by the trained clinician. The progression of Ekso settings allows the patient to use their maximum effort while the Ekso assists only as much as the patient requires to complete stepping. Patients may also spend time working on pre-gait activities and balance activities including weight shifting, stepping in place, side-stepping and backwards ambulation based on the patient's needs as determined by the clinician.
Study NCT05241457 — intervention group
Intervention type: PROCEDURE
Intervention: Standard physical therapy
Description: Standard physical therapy sessions will be 60 to 90 minutes a day. Clinicians typically focus on gait, balance, and strengthening activities that address goals related to functional mobility. Other devices that would normally be used during PT sessions, including the Lite Gait and Rifton tram body weight support devices and electrical stimulation devices including the XCITE and RT300 (from Restorative Therapies).
Study NCT03426254 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injections Subcutaneously Talazoparib
Description: Patients receive per day single dose of subcutaneous Injection contains 1 mg Talazoparib on days 1-28
Study NCT03426254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral capsules Talazoparib
Description: Patients receive 1 mg of Talazoparib PO QD on days 1-28.
Study NCT05581667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: post isometric relaxation
Description: PIR is performed by first passively lengthening the muscle, then having the patient lightly contract (10-20% of maximum) against resistance for 5 seconds passively before exhaling and relaxing the muscle and repeated. The clinician then takes up the slack within the muscle and repeats the technique 3 to 5 times
Study NCT05581667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swedish Massage
Description: classic Swedish massage for the cervical and upper thoracic region. Massage is a method that is applied to superficial soft tissues such as muscles, skin, ligaments and fascia and structures located under the superficial tissues and aims to relax.
Study NCT05020431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological measuring of collagen fragments biomarker during orthodontic tooth movement
Description: Biological measure the levels of type I collagen fragments ICTP and CTX levels in the GCF and saliva during initial leveling and alignment in adolescent patients treated with fixed orthodontic appliances.
Study NCT04754477 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Osseointegrated Steady-State Implant System (OSI)
Description: System includes the OSI200 implant surgically placed under the skin behind the ear, the BI300 implant osseointegrated in the bone and the external Osia 2 sound process
Study NCT06416553 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Home-based transcranial direct current stimulation- real tDCS
Description: Home-based transcranial direct current stimulation- anode over right STG, cathode over left STG, 2 mA stimulation with 1x1 tDCS mini-CT device by Soterix Medical
Study NCT06416553 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Home-based transcranial direct current stimulation- sham tDCS
Description: Home-based transcranial direct current stimulation- anode over right STG, cathode over left STG, sham stimulation with tDCS mini-CT device by Soterix Medical
Study NCT06416553 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lee-Silverman voice treatment
Description: Remote Lee Silverman Voice Treatment (LSVT) delivered via telepractice by speech therapist. LSVT is a high-effort speech therapy that is primarily focused on improving speech loudness during 16 individual one-hour sessions in one month.
Study NCT06416553 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Lee-Silverman voice treatment
Description: Remote Lee Silverman Voice Treatment (LSVT) delivered via telepractice by speech therapist. LSVT is a high-effort speech therapy that is primarily focused on improving speech loudness during 16 individual one-hour sessions in one month.
Study NCT05866926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FAB122
Description: FAB122 Daily dose 100 mg
Study NCT06494202 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Innovative rehabilitation
Description: Conventional rehabilitation program associated with innovative therapies.
Study NCT06494202 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation program.
Description: Conventional rehabilitation program
Study NCT06494202 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional rehabilitation program.
Description: Conventional rehabilitation program
Study NCT05540054 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Respiratory muscle strengthening training will be given with a resistive threshold inspiratory muscle strengthening device.
Study NCT05540054 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard pulmonary rehabilitation programme
Description: The standard PR consisted of breathing exercises, peripheral muscle strengthening and self walking training.
Study NCT05617911 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Cuff
Description: Blood Flow Restriction (BFR) involves the application of an external device to reduce arterial blood flow to the exercising area, while largely occluding venous return from that same area.
Study NCT05617911 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham and standard of Care Therapy
Description: SoC PT + non-inflated BFR cuff
Study NCT05078320 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure and response prevention (ERP)
Description: The treatment is Internet-delivered and therapist-guided, involving both the adolescent and at least one parent. The treatment consists of two separate sets of modules, one for the adolescent and one for the parent, each with separate logins. The ICBT intervention consists of 12 modules, delivered over a maximum of 14 weeks.~The main goal of treatment is to help the young person to stop avoiding anxiety-provoking situations by undertaking exposure tasks and to stop doing unhelpful repetitive behaviours and rituals, known as response prevention. Every module also contains homework tasks that mainly consists of exposure and response prevention (ERP).~Parents are also often involved in the patients' rituals and avoidant behaviours (known as family accommodation), which may contribute to maintain the BDD symptoms. Involving parents facilitates modification of these unhelpful patterns.
Study NCT05925166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTNFR-Fc
Description: Subjects will receive 50 mg of study drug on visit 1. A second dose of study drug will be administered if the pain intensity is ≥ 5 on a pain scale of 0-10 at Visit 2
Study NCT05925166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: Subjects will be administered triamcinolone acetonide 40 mg intramuscularly on visit 1. A second dose of drug will be administered if the pain intensity is ≥ 5 on a pain scale of 0-10 at Visit 2
Study NCT04705636 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connected device named Leo from Ludocare society
Description: Connected device named Leo from Ludocare society will be allocated to each child for three-months period. During this time, child will be helped to take all of his medication and specific care by this connected device.
Study NCT05664386 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: propofol 2～2.5mg/kg was used for anesthesia induction. propofol is an intravenous sedative-hypnotic and a short-acting GABAA receptor agonist. It activates GABAergic neurons by enhancing chloride ion influx. It is used for anesthesia of induction and maintenance.
Study NCT05664386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciprofol
Description: Ciprofol 0.4～0.5mg/kg was used for anesthesia induction. Ciprofol is an intravenous sedative-hypnotic and a short-acting GABAA receptor agonist. It activates GABAergic neurons by enhancing chloride ion influx. It is used for anesthetic induction and maintenance agents include rapid induction of general anesthesia, rapid recovery of consciousness, minimal residual effects on the central nervous system and less injection pain.
Study NCT05868174 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 89Zr-TLX250
Description: Single IV administration followed by 89Zr-DFO-girentuximab PET/CT (or PET/MRI) scan at screening and approximately 8-10 weeks (±1 week) after Cycle 3 Day 1, as well as at the end of treatment visit (if feasible). The PET/CT should be obtained within 4-7 days after 89Zr-TLX250 administration
Study NCT05868174 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 177Lu-TLX250 and Peposertib
Description: Dose escalation and de-escalation for the determination of the Maximum tolerated combination/ Recommended phase 2 dose.~All subjects will receive 177Lu-TLX250 intravenously on day 1 and Peposertib BID on days 4-21 of each 84-day cycle.
Study NCT05337852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emotional Freedom Technique
Description: To the pregnant women in the experimental group; Emotional freedom technique was applied online with the researcher twice a week. The release protocol of EFT was taught to the participants and it was applied between the interviews made by the researcher. Whether the participant did the application or not was confirmed by phone and a homework schedule was used for smooth follow-up.~* PUQE, PRAQ-2 tests will be applied before the intervention,~* SUE and PUQE will be applied before and after each session,~* After 2 sessions, post-test data will be obtained with PUQE, SUE, PRAQ-2.
Study NCT05525611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabergoline 0.5 MG
Description: Cabergoline 0.5 mg once a week in 12 weeks
Study NCT05525611 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once a week in 12 weeks
Study NCT05610748 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sub-Periosteal Peri-implant Augmented Layer technique
Description: In patients assigned to the SPAL group, the management of the soft tissues will be performed according to the SPAL technique as originally described by Trombelli et al. (2018). Implant site preparation will be performed using a set of calibrated guided surgery steel burs under copious sterile saline irrigation. Implants will be placed, and a healing abutment will be positioned and screwed. The space underneath the periosteal layer will be then filled with a deproteinized bovine bone mineral (DBBM) graft. A sterile viscoelastic gel (SVG) based on polynucleotides and hyaluronic acid (REGENFAST®, Mastelli Srl, Sanremo, Italia) will be combined with the bone graft. The periosteal layer will be then secured to the oral flap by mean of 6/0 resorbable internal mattress sutures. SVG wil be placed underneath the mucosal layer and the latter will be coronally advanced and stabilized a using 6/0 resorbable internal mattress and sling sutures.